Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03953417 · ClinicalTrials.gov registry record · NA

Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression

A NA study of Treatment-Resistant Depression, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
7
Enrollment target
1
Study location

NCT03953417: Completed NA study of Treatment-Resistant Depression, sponsored by Stanford University.

NCT03953417 is a NA study of Treatment-Resistant Depression that has completed, run by Stanford University. The registered enrollment target is 7 participants, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03953417, a NA study of Treatment-Resistant Depression, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant bipolar depression. In this open-label study, all participants will receive accelerated theta-burst stimulation.

Primary Outcome

A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. The MADRS consists of ten questions. Each interview question is rated from 0 to 6 with an overall score of 60 or less. Higher scores indicate increasing depressive symptoms. A total score of 0 to 6 indicates the absents of depressive symptoms, 7 to 19 indicates mild depressive symptoms, 30 to 34 indicates moderate depressive symptoms, 35 to 60 indicates severe depressive symp

Conditions Studied

Treatment-Resistant Depression

Interventions

  • DEVICE Accelerated intermittent theta-burst treatment

Study Locations (1)

California

  • Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2019-07-01
Est. Completion 2023-12-30
Phase NA
Stanford University

1,744 total trials

What the finished NCT03953417 record still lists

NCT03953417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Accelerated intermittent theta-burst treatment is the first listed.

NCT03953417 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03953417 about?

NCT03953417 is a clinical study titled "Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression". This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant bipolar depression. In this open-label study, all participants will receive accelerated theta-burst stimulation.

What is the current status of trial NCT03953417?

This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2019-07-01. Estimated completion is 2023-12-30.

What conditions does trial NCT03953417 study?

This clinical trial studies the following conditions: Treatment-Resistant Depression.

What interventions are being tested in trial NCT03953417?

The interventions under investigation include: Accelerated intermittent theta-burst treatment (DEVICE).

Who is sponsoring clinical trial NCT03953417?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03953417 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Treatment-Resistant Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03953417's enrollment target sits among peer trials

7 53rd of 54 higher than 2 of 54 other Treatment-Resistant Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03953417, the US trial registry maintained by the National Library of Medicine. NCT03953417 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.